A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene - PubMed (original) (raw)

Comparative Study

A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene

Y Guilloux et al. J Exp Med. 1996.

Abstract

A cytolytic T lymphocyte (CTL) clone that lyses many HLA-A2 melanomas was derived from a population of tumor-infiltrating lymphocytes of an HLA-A2 melanoma patient. The gene coding for the antigen recognized by this CTL was identified by transfection of a cDNA library. It is the gene which has been reported to code for N-acetylglucosaminyltransferase V (GnT-V). Remarkably, the antigenic peptide recognized by the CTL is encoded by a sequence located in an intron. In contrast to the fully spliced GnT-V mRNA, which was found in a wide range of normal and tumoral tissues, the mRNA containing the intron region coding for the antigen was not found at a significant level in normal tissues. This mRNA was observed to be present in about 50% of melanomas. Our results suggest that a promoter located near the end of the relevant intron is activated in melanoma cells, resulting in the production of an mRNA coding for the antigen.

PubMed Disclaimer

Similar articles

• T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
  Sensi M, Salvi S, Castelli C, Maccalli C, Mazzocchi A, Mortarini R, Nicolini G, Herlyn M, Parmiani G, Anichini A. Sensi M, et al. J Exp Med. 1993 Oct 1;178(4):1231-46. doi: 10.1084/jem.178.4.1231. J Exp Med. 1993. PMID: 8376931 Free PMC article.
• Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage.
  Lupetti R, Pisarra P, Verrecchia A, Farina C, Nicolini G, Anichini A, Bordignon C, Sensi M, Parmiani G, Traversari C. Lupetti R, et al. J Exp Med. 1998 Sep 21;188(6):1005-16. doi: 10.1084/jem.188.6.1005. J Exp Med. 1998. PMID: 9743519 Free PMC article.
• A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.
  Coulie PG, Brichard V, Van Pel A, Wölfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP, Renauld JC, Boon T. Coulie PG, et al. J Exp Med. 1994 Jul 1;180(1):35-42. doi: 10.1084/jem.180.1.35. J Exp Med. 1994. PMID: 8006593 Free PMC article.
• Genes coding for tumor antigens recognized by human cytolytic T lymphocytes.
  Coulie PG, Weynants P, Lehmann F, Herman J, Brichard V, Wölfel T, Van Pel A, De Plaen E, Brasseur F, Boon T. Coulie PG, et al. J Immunother Emphasis Tumor Immunol. 1993 Aug;14(2):104-9. doi: 10.1097/00002371-199308000-00004. J Immunother Emphasis Tumor Immunol. 1993. PMID: 8280701 Review.
• Recognition of shared melanoma antigens by human tumor-infiltrating lymphocytes.
  Topalian SL, Hom SS, Kawakami Y, Mancini M, Schwartzentruber DJ, Zakut R, Rosenberg SA. Topalian SL, et al. J Immunother (1991). 1992 Oct;12(3):203-6. doi: 10.1097/00002371-199210000-00013. J Immunother (1991). 1992. PMID: 1445813 Review.

Cited by

• Cancer neoepitopes viewed through negative selection and peripheral tolerance: a new path to cancer vaccines.
  Srivastava PK. Srivastava PK. J Clin Invest. 2024 Mar 1;134(5):e176740. doi: 10.1172/JCI176740. J Clin Invest. 2024. PMID: 38426497 Free PMC article. Review.
• The landscape of T cell antigens for cancer immunotherapy.
  Peri A, Salomon N, Wolf Y, Kreiter S, Diken M, Samuels Y. Peri A, et al. Nat Cancer. 2023 Jul;4(7):937-954. doi: 10.1038/s43018-023-00588-x. Epub 2023 Jul 6. Nat Cancer. 2023. PMID: 37415076 Review.
• Immunogenic cell death in cancer: concept and therapeutic implications.
  Galluzzi L, Kepp O, Hett E, Kroemer G, Marincola FM. Galluzzi L, et al. J Transl Med. 2023 Mar 2;21(1):162. doi: 10.1186/s12967-023-04017-6. J Transl Med. 2023. PMID: 36864446 Free PMC article. Review.
• Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics.
  Lozano-Rabella M, Garcia-Garijo A, Palomero J, Yuste-Estevanez A, Erhard F, Farriol-Duran R, Martín-Liberal J, Ochoa-de-Olza M, Matos I, Gartner JJ, Ghosh M, Canals F, Vidal A, Piulats JM, Matías-Guiu X, Brana I, Muñoz-Couselo E, Garralda E, Schlosser A, Gros A. Lozano-Rabella M, et al. Clin Cancer Res. 2023 Jun 13;29(12):2250-2265. doi: 10.1158/1078-0432.CCR-22-3298. Clin Cancer Res. 2023. PMID: 36749875 Free PMC article.
• Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.
  Alarcon NO, Jaramillo M, Mansour HM, Sun B. Alarcon NO, et al. Pharmaceutics. 2022 Jul 11;14(7):1448. doi: 10.3390/pharmaceutics14071448. Pharmaceutics. 2022. PMID: 35890342 Free PMC article. Review.

References

1. 1. Science. 1987 May 1;236(4801):582-5 - PubMed
2. 1. Proc Natl Acad Sci U S A. 1987 May;84(10):3365-9 - PubMed
3. 1. J Immunol Methods. 1989 May 12;119(2):203-10 - PubMed
4. 1. Oncogene. 1989 Jul;4(7):853-60 - PubMed
5. 1. Int J Cancer. 1989 Oct 15;44(4):634-40 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information

• Research Materials

  • Cellosaurus - a cell line knowledge resource
  • NCI CPTC Antibody Characterization Program